Unter den Linden 10
Berlin 10117
Germany
49 30 700 140 449
https://www.aladdinid.com
Settore/i: Healthcare
Settore: Health Information Services
Impiegati a tempo pieno: 3
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Wade Menpes-Smith | Chairman of the Board, CEO & MD | N/D | N/D | N/D |
Mr. Bimal Shah | Deputy Chairman & COO | N/D | N/D | N/D |
Mr. Hamish Badenoch | CFO & Director | N/D | N/D | N/D |
Prof. David C. Rubinsztein | Member of Drug Discovery Advisory Board & Chief Scientific Advisor | N/D | N/D | N/D |
Mr. Paul Sitoh | Head of Blockchain Technology | N/D | N/D | N/D |
Aladdin Healthcare Technologies SE, through its subsidiary, Aladdin Healthcare Technologies Ltd, develops software solutions for the storage and management of health information using blockchain technology. The company provides Artificial Intelligence assisted Drug Discovery platform to identify various small molecule drug compounds with multiple age-related diseases, including Alzheimer's, Parkinson's, and SARS-CoV-2; PharmaKG, a biomedical knowledge graph; and Disease Diagnosis and Risk Assessment Platform. The company was founded in 2014 and is based in Berlin, Germany.
L'ISS Governance QualityScore di Aladdin Healthcare Technologies SE al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.